States across the country are experimenting with Prescription Drug Affordability Boards (PDABs) to address the price of medicine. Each state has a different approach. Several exist to negotiate supplemental Medicaid rebates; others make recommendations to limit costs. A third group of PDABs has the power to set state-wide upper payment limits that cap the amount pharmacy or provider can pay to buy a medicine and the amount they can be reimbursed for it. These boards have spent more than 200 hours and over $16 million in taxpayer dollars trying to implement changes to lower costs since 2020.

So far, they haven't succeeded.

• Learn why PSM opposes upper payment limits.
• Catch up on PDAB activity.
• Download this handout.